title: [Biomarkers for early diagnosis of Alzheimer's disease].
abstract: Alzheimer's disease is responsible for 40-50% of dementia cases. Future treatment may include disease-modifying compounds unlikely to be efficient if administered late in the course, thus necessitating early diagnosis. Furthermore, revised diagnostic research criteria that include biomarkers of pathological accumulation of cortical beta-amyloid (decreased beta-amyloid in cerebrospinal fluid and amyloid imaging) and neurodegeneration (structural MRI and 18F-FDG-PET), have been published. Future research is needed to determine specific evidence-based application of these biomarkers in the clinic as well as discovery of novel biomarkers.
authors.affiliation: Nationalt Videnscenter for Demens, Neurologisk Klinik, Neurocentret, Rigshospitalet, Blegdamsvej 9, 2100 København Ø. kristian.steen.frederiksen@regionh.dk.
authors.forename: Kristian S
authors.initials: KS
authors.lastname: Frederiksen
authors.forename: Steen
authors.initials: S
authors.lastname: Hasselbalch
authors.forename: Ian
authors.initials: I
authors.lastname: Law
authors.forename: Liselotte
authors.initials: L
authors.lastname: Højgaard
authors.forename: Gunhild
authors.initials: G
authors.lastname: Waldemar
mesh_terms: D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000000981:diagnostic imaging / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid / Q000378:metabolism; D015415:Biomarkers / Q000134:cerebrospinal fluid* / Q000378:metabolism; D042241:Early Diagnosis; D006801:Humans; D008279:Magnetic Resonance Imaging; D049268:Positron-Emission Tomography / Q000379:methods*; D012680:Sensitivity and Specificity
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers